PT  - JOURNAL ARTICLE
AU  - Cardet, Juan Carlos
AU  - Bailey, Jonathan M.
AU  - Hurley, Laura P.
AU  - Maher, Nancy E.
AU  - Staton, Elizabeth W.
AU  - Yawn, Barbara P.
AU  - Zaeh, Sandra E.
AU  - Israel, Elliot
AU - on behalf of other PREPARE investigators;
AU  - Apter, Andrea J.
AU  - Bradford, Phuong
AU  - Calderon-Candelario, Rafael A.
AU  - Carroll, Jennifer K.
AU  - Chupp, Geoffrey L.
AU  - Cohen, Rubin
AU  - Ericson, Brianna
AU  - Fuhlbrigge, Anne L.
AU  - Kaplan, Barbara M.
AU  - Kruse, Jean M.
AU  - Nazario, Sylvette
AU  - Pace, Wilson D.
AU  - Pasarica, Magdalena
AU  - Phipatanakul, Wanda
AU  - Riley, Isaretta L.
AU  - Rodriguez-Louis, Jacqueline
AU  - Shenoy, Kartik
AU  - Stranges, Paul M.
AU  - Tapp, Hazel
AU  - Wechsler, Michael E.
TI  - Maintenance of an Asthma Intervention Post-Trial: Use of a Patient-Activated Reliever-Triggered Inhaled Corticosteroid (PARTICS) Strategy in Black and Latinx Patients
AID  - 10.3122/jabfm.2024.240014R2
DP  - 2025 Mar 01
TA  - The Journal of the American Board of Family
                Medicine
PG  - 378--382
VI  - 38
IP  - 2
4099  - http://www.jabfm.org/content/38/2/378.short
4100  - http://www.jabfm.org/content/38/2/378.full
SO  - J Am Board Fam Med2025 Mar 01; 38
AB  - Purpose: A Patient-Activated Reliever-Triggered Inhaled Corticosteroid (PARTICS) strategy of enhancing usual care with rescue short-acting beta agonist (SABA) supplemented with inhaled corticosteroid (ICS) reduces asthma exacerbations vs. usual care alone in Black and Latinx adults with moderate-severe asthma. We investigated post-trial PARTICS usage and patient perceptions of efficacy.Methods: PREPARE trial participants randomized to the PARTICS intervention were surveyed an average of 29 months after trial exit.Results: Of 600 PARTICS-assigned PREPARE trial participants, 505 consented to future research. Fifty-two percent (262/505) completed this survey. Forty-one percent (108/262) continued using PARTICS post-trial. Of these, 97% (105/108) reported that PARTICS helped to control their asthma. Thirty-four percent (37/108) switched from the trial provided QVAR® to other ICS brands due to insurance coverage or clinician issues (e.g., unwillingness to prescribe or misunderstanding of PARTICS; 65%, 24/37). Of those who stopped using PARTICS post-trial (59% [154/262]), 62% (95/154) reported using PARTICS until the PREPARE-provided ICS inhaler ran out, and 31% (47/154) reported not knowing that their asthma care clinician could prescribe it. Only 2% (5/154) of those not using PARTICS reported that it had not been helpful for asthma.Conclusions: Continued PARTICS use was common >2 years post-trial despite minimal study instruction and was perceived as helpful for asthma, suggesting that patients will likely adopt this strategy if implemented at a healthcare system level.